Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD

Blood (2016) 128 (22): 3095.

https://doi.org/10.1182/blood.V128.22.3095.3095

Published: 2016

Journal Articles

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, MD, Yun Su, MD MPH, Elias J. Jabbour, MD, Helen Bhattacharyya, PhD, Eric Yan, PhD, Mark Shapiro, MD PhD, Joseph C. Cappelleri, PhD MPH, MS, David I. Marks, MD PhD

Blood (2016) 128 (22): 1599.

https://doi.org/10.1182/blood.V128.22.1599.1599

Published: 2016

Journal Articles

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

Vamsi Kota, MD, Tim H. Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Jorge E. Cortes, MD, Jeffrey H. Lipton, MD PhD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Fiona An, MD, Eric Leip, PhD, Rocco J. Crescenzo, DO, FACOI, Mabel Woloj, PhD, Mark Shapiro, MD PhD, H. Jean Khoury, MD FACP

Blood (2016) 128 (22): 1921.

https://doi.org/10.1182/blood.V128.22.1921.1921

Published: 2016

Journal Articles

The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Stuart L. Goldberg, MD, Yun Su, MD MPH, MS, Candace Gunnarsson, EdD, MA, William D Irish, PhD, Michael Ryan, MS, Mabel Woloj, MD, Roxanne Ferdinand, MBBS MRCP MFPM, Mark Shapiro, MD

Blood (2015) 126 (23): 2797.

https://doi.org/10.1182/blood.V126.23.2797.2797

Published: 2015

Journal Articles

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Jorge E. Cortes, Tim H. Brümmendorf, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Sashi Nadanaciva, D Phil, Nathalie Bardy-Bouxin, PhD, Mark Shapiro, MD, Eric Leip, PhD, Jeffrey H. Lipton, MD PhD, Carlo Gambacorti-Passerini, MD

Blood (2015) 126 (23): 4041.

https://doi.org/10.1182/blood.V126.23.4041.4041

Published: 2015

Journal Articles

Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study

Tim H. Brümmendorf, MD, Jorge E. Cortes, MD, H. Jean Khoury, Hagop M. Kantarjian, MD, Dong-Wook Kim, MD PhD, Philippe Schafhausen, MD, Mirjana Zeremski, MD, Mark Shapiro, MD, Eric Leip, PhD, Carlo Gambacorti-Passerini, MD, Jeffrey H. Lipton, MD PhD

Blood (2014) 124 (21): 5544.

https://doi.org/10.1182/blood.V124.21.5544.5544

Published: 2014

Journal Articles

Real World Analysis Of Duration Of TKI Treatment Among Patients With Chronic Myeloid Leukemia

Henry J Henk, PhD, Mabel Woloj, PhD, Mark Shapiro, MD, PhD, Jennifer Whiteley, EdD

Blood (2013) 122 (21): 5175.

https://doi.org/10.1182/blood.V122.21.5175.5175

Published: 2013

Journal Articles

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Luis Fayad, Hemant Patel, PhD, Gregor Verhoef, Mitchell R. Smith, Peter W.M. Johnson, MD, FRCP, Myron S. Czuczman, MD, Bertrand Coiffier, Georg Hess, Eva Gine, Anjali Advani, MD, Fritz Offner, MD, Erik R. Vandendries, MD, PhD, Mark Shapiro, MD, PhD, FACP, Nam H. Dang, MD, PhD

Blood (2008) 112 (11): 266.

https://doi.org/10.1182/blood.V112.11.266.266

Published: 2008

Journal Articles

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Luis Fayad, MD, Hemant Patel, PhD, Gregor Verhoef, MD, PhD, Myron Czuczman, MD, James Foran, MD, Eva Gine, MD, Ama Rohatiner, MD, Mitchell R. Smith, MD, Mark Shapiro, MD, PhD, Anjali Advani, MD

Blood (2006) 108 (11): 2711.

https://doi.org/10.1182/blood.V108.11.2711.2711

Published: 2006

NARROW

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia

The Effect of Vascular Occlusive Events on Discontinuation and Cost of Care in Patients Treated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib

Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study

Real World Analysis Of Duration Of TKI Treatment Among Patients With Chronic Myeloid Leukemia

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only